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In 2015, 4062 unaccompanied minor refugees were registered in Berlin, Germany. Accord-
ing to national policies, basic clinical examination and tuberculosis (TB) screening is a pre-
requisite to admission to permanent accommodation and schooling for every refugee. This
article evaluates the use of an interferon-γ-release-assay (IGRA) during the initial examina-
tion and TB screening of 970 unaccompanied minor refugees.
Results
IGRA test were obtained during TB screening for 301 (31.0%) of 970 adolescents not previ-
ously screened for TB. Positive IGRA results were obtained in 13.9% (42/301). Most of the
42 IGRA-positive refugees originated from Afghanistan or Syria (n?20 and 10 respectively).
Two IGRA-positive adolescents were lost to follow-up, 2 were diagnosed with TB and the
remaining 38 diagnosed with latent TB infection (LTBI). Demographic features of the 40
patients with positive IGRA result were as follows: 39 male, median age 16.8 years (IQR
16.0–17.2y), none meeting underweight criteria (median BMI 21.3kg/m2). On initial chest X-
ray 2/40 participants had signs of active TB, while in 38 active disease was excluded and
the diagnosis of latent TB infection (LTBI) made. Active hepatitis B-co-infection was diag-
nosed in 3/38 patients. All patients with LTBI received Isoniazid and Rifampicin for 3 months
without occurrence of severe adverse events. The most frequently observed side effect was
transient upper abdominal pain (n = 5). Asymptomatic elevation of liver transaminases was
seen in 2 patients. 29 patients completed treatment with no signs of TB disease at the end
of chemoprevention and 9 were lost to follow up.
Conclusion
Screening for TB infection in minor refugees was feasible in our setting with a relatively high
rate of TB infection detected. Chemopreventive treatment was tolerated well regardless of
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underlying hepatitis-B-status. Minor refugees migrating to Germany should be screened for
TB infection, instead of TB disease only, regardless of the background TB incidence.
Introduction
In 2015, around 1.1 million refugees were registered in Germany with estimated 40,000–
60,000 unaccompanied minor refugees. Most of the unaccompanied minors originated from
Afghanistan (34%), Syria (31%), Iraq (8.4%), Eritrea (8.1%) and Somalia (4.5%) [1]. In the city
of Berlin, 4062 minor refugees were registered in 2015.
According to German national policies, every refugee has to undergo basic clinical exami-
nation and infectious tuberculosis (TB) is to be ruled out as soon as possible after entry to the
country. This is a prerequisite to admission to permanent accommodation and schooling.
Besides, vaccinations against tetanus, diphtheria, pertussis, poliomyelitis, mumps, measles and
rubella are offered in case of incomplete or unknown immunization status.
TB screening is based on a chest X-ray in persons older than 15 years of age. In those youn-
ger than 15 years of age, making about 25% of all refugees, an interferon-γ-release-assay
(IGRA) or the tuberculin skin test (TST) have been proposed for screening purposes [2] [3]. In
case of symptoms of TB or a positive TST or IGRA a chest radiograph is obtained also in those
being under 15 years of age.
A previous study informs about screening for infectious diseases except tuberculosis in
minor refugees [4]. But regarding the burden of TB infection and TB disease, a substantial lack
of knowledge exists for this cohort.
In many unaccompanied minors no TB screening or vaccinations were performed upon
arrival to Germany, impeding schooling and further integration, because special initial accep-
tance facilities, so-called clearing offices, for unaccompanied minor refugees had to be estab-
lished. Additionally, there was uncertainty on how to perform medical procedures in lack of a
legal guardian.
In an action campaign in January 2016, initiated by the Charite´—Universita¨tsmedizin Ber-
lin (“Charite´ hilft”), unaccompanied refugees <18 years of age residing in Berlin were offered
initial basic clinical examination, TB screening as well as the vaccinations mentioned above.
For logistical reasons, an IGRA (QuantiFERON1-TB Gold In-Tube) was performed in those
not having received TB screening (either TST, IGRA or chest-X-ray) before regardless of age.
This article provides information on the initial tuberculosis screening of unaccompanied
minor refugees, focusing on those with positive IGRA results. Participants diagnosed with TB
or latent tuberculosis infection (LTBI) received treatment according to national standard of
care and were followed up prospectively. This data also adds to the limited body of evidence
on chemopreventive TB treatment in adolescents, an age-group being considered as being
more susceptible to drug induced hepatotoxicity compared to younger children [5, 6].
Methods
Local authorities as well as several local charity organizations caring for unaccompanied
minor refugees were contacted and informed about the screening campaign and asked to
inform the refugees they care for. All minors participating received information on the screen-
ing and vaccination procedures in their mother tongue beforehand and were asked for written
consent. Additionally, a questionnaire on the medical history including information on previ-
ous TB screening was asked to be filled in. Inclusion criteria were children and adolescents
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younger than 18 years of age with no signs of acute illness. In case of acute illness, the person
was referred to a local medical service. At the day of the screening, interpreters of all languages
mainly spoken by the refugees were available.
Participants were interrogated for any symptoms or complains and received a basic clinical
examination. In case no TB screening had been performed, blood for the IGRA-test was taken
by venipuncture. Vaccinations were offered if evidence of a complete immunization status was
missing.
Blood samples for IGRA tests were transferred to the laboratory at site within two hours.
Participants with a positive IGRA test (IFN-γ> 0.35 IU/mL) were followed up in the paediat-
ric infectious disease clinic of the Charite´ University medicine. A chest X-ray was performed.
In the absence of signs for active TB, the diagnosis of LTBI was made and chemopreventive
treatment recommended. According to national guidelines, 3 months of isoniazid (INH) in
combination with rifampicin (RMP) are recommended for chemopreventive therapy if no
drug resistance was suspected. Because the index cases were not known in our cohort, suscep-
tibility to INH and RMP was assumed and treatment started accordingly. In case of signs for
TB disease, further diagnostic procedures according to national standards were performed and
TB treatment initiated accordingly.
Before initiation of chemopreventive treatment, a baseline laboratory examination includ-
ing whole blood cell count, liver transaminases, alkaline phosphatase, creatinine, uric acid and
hepatitis B and C serology was performed. Patients were followed up clinically and laboratory
tests were repeated after 2 and 6 weeks. At each follow-up visit, adherence was checked by
either interrogation, pill count or inspection of urine for red-orange-coloring (due to RMP
intake). Before chemoprevention was stopped and if possible one year after the end of chemo-
prevention, further chest X-rays were performed to exclude development of TB disease due to
non-adherence, drug resistance or treatment failure.
Results
Nine-hundred-seventy adolescents (median age 16.8 years, range 13.6–17.1years) participated
in the screening campaign. Of 970 participants, 301 had not been screened for TB. The leading
countries of origin of these participants were Afghanistan (125/301; 41.5%), Syria (69/301;
22.9%), Lebanon and Iran (both 14/301, 4.7%). 26 adolescents (8.6%) refused to indicate their
country of origin. An IGRA-test was performed for TB screening, with 42 (13.9%) tested posi-
tive (see Table 1 for distribution according to country). Two of these adolescents were lost to
follow-up, the remaining 40 were seen at the paediatric infectious disease clinic Charite´ Uni-
versity Medicine, Berlin.
Demographic features of this cohort were as follows: 39 male, 1 female, median age 16.8
years (IQR 16.0–17.2y), median weight 62.5kg (IQR 58.4–66.5), median BMI 21.3kg/m2 (IQR
20.3–22.6kg/m2). Therefore, none of the participants met underweight criteria [7]. Positive
IGRA-test results varied from 0.39–15.46 IU/ml (median 3.39IU/ml). In the adolescent with
an IGRA-result of 0.39IU/ml a repeated test one month later showed a result of 1.26IU/ml.
The initial chest X-ray showed signs of intrathoracic TB in 2 cases (one from Syria, one
from Afghanistan) being transferred to a paediatric clinic for further diagnostic work-up and
treatment. One of these adolescents reported weight loss and fatigue, but both did not have
symptoms like persistent cough or night sweats. One patient had hilar lymphnode TB and the
other pulmonary TB, both without detection of M. tuberculosis in sputum. In another adoles-
cent with positive IGRA-test, a small pleural effusion was suspected that cleared without treat-
ment. A further patient reported of cough for more than 8 days and night sweats without
weight loss, but had a normal chest X-ray.
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In 38 adolescents, the diagnosis of LTBI was made and chemoprevention with 3 months
INH/RMP recommended. Four patients were seen at the initial visit only. Of 29 patients seen
at 3 months before stopping treatment, 10 had been seen for follow up visits while being on
chemopreventive therapy once and 19 twice, respectively. Four patients were seen during
treatment, but lost to follow up at the 12 weeks visit. Main reason for lost to follow up was relo-
cation to another city. At the three months visit, a chest X-ray was taken again before chemo-
prevention was stopped. Twenty-eight of 29 chest X-rays were reported to be normal. Nine
patients received a chest x-ray one year after completion of chemoprevention and none devel-
oped TB. In one patient, very small (<1 cm) opacifications with calcifications in the right
Table 1. Country of origin of participants according to WHO world regions[37], number of participants receiving interferon-γ-release-assay (IGRA) -testing
(n = 301) and numbers of positive (IGRA) test results (n = 42) according to country of origin.
World region of origin Number
participants
IGRA test positive/ number tested per world
region
Country of origin IGRA test positive/ number tested per
country


































Unknown 57 4/26 4/26
Total 970 42/301 42/301
https://doi.org/10.1371/journal.pone.0216234.t001
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upper lobe were detected in the follow-up chest X-rays that had been missed in the initial
report. In this patient, the diagnosis of previous TB was made retrospectively.
Testing for hepatitis B and C was performed in 38/38 cases, and active hepatitis B infection
was diagnosed in 3 cases. Initial viral load was 178, 105 and>70 000 000 HBV-DNA IE/ml,
respectively. There was no case of hepatitis C. Baseline liver transaminases were slightly ele-
vated (< 3times upper limit) in 3 cases of which 1 had active hepatitis B. This patient had a
viral load >70.000,000IE/ml and was started on treatment with entecavir at the end of chemo-
preventive TB treatment. Anaemia was found at baseline in 3 patients (minimal Hb 9.0g/dl);
no further abnormalities were noted.
Non-adherence was suspected in 10 adolescents during treatment followed by counselling
again. At the end of treatment non-adherence was only suspected in 1/29 patients. No severe
adverse events occurred and treatment had not to be stopped due to side effects in any case.
Transient upper abdominal pain was reported in 5 cases. One patient with chronic hepatitis B
had permanent gastric discomfort. One patient complained about alopecia. Asymptomatic ele-
vation of liver transaminases above 3 times upper normal limit (but <5times upper normal
limit) occurred in two patients (one chronic hepatitis B co-infection). Patients were monitored
for signs of increased hepatotoxicity, but therapy could be continued until completion of 3
months therapy. Transaminases normalized or decreased with cessation of treatment with
INH and RMP.
Discussion
Concordant with official German refugee reports, the majority of our cohort originated from
Afghanistan and Syria. According to WHO country reports, Afghanistan has a TB incidence
of 189/100.000, while Syria is considered a low TB burden country with an estimated incidence
of 19/100.000 [8]. For comparison, TB incidence was 7.2/100.000 in Germany in 2016 [9].
Two patients of our cohort with a positive IGRA (n = 42) had radiographic signs of active
TB. Because persons with acute illness were excluded from our campaign, the true burden of
TB in refugee minors might have been underestimated. Comparison with other studies is chal-
lenging because of the large diversity of policies on TB and TB infection screening in European
countries [10]. In some European countries (e.g. Netherlands, Sweden, Spain) TB screening is
restricted to asylum seekers originating from countries with a TB-incidence of more than 40-
100/100 000, while others aim to screen all asylum seekers (e.g. Belgium, Germany) regardless
of TB incidence in home countries according to WHO estimates [10]. In Switzerland, symp-
tom triage screening is performed and only those classified as being at risk for TB are screened
further using a chest X-ray (www.tb-screen.ch). Besides the targeted population, the target of
TB screening itself varies from country to country. Sometimes, a TST or an IGRA is performed
to detect tuberculosis infection (mainly in children or younger adults) while other focus on
tuberculosis disease and primarily only a chest x-ray is taken.
In a study on a large cohort (n = 2936) of unaccompanied minors seeking asylum in Swe-
den in 2015, Bennet et al. reported numbers of TB disease of 500-3400/100,000 [11]. According
to Swedish policy, screening is restricted to migrants from countries with a TB burden of more
than 100/100,000 or if the screening doctor found other risk factors for TB. Therefore, 82% of
the Swedish cohort originated from high burden countries (HBC), while in our study as well
as in a further German pediatric study, migrants from HBC, besides Afghanistan, only form a
small minority [12].
These higher numbers of TB found in the study by Bennet et al. as well as in our study are
likely attributable to a high risk for both, TB infection and progression to disease, under condi-
tions of conflict or humanitarian crisis in the country of origin as well as during transit to
TB screening and treatment in minor refugees in Germany
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Europe [13]. Depending on many factors like background TB incidence, access to health care,
nutrition, overcrowding, transit time, migration route and others, estimates of TB incidence
can often dramatically exceed TB incidence of the country of origin [13] [14]. Transit time was
asked for in all refugee minors of our cohort, but responds were often very imprecise or
refused.
In our study, both adolescents with TB disease would have been missed in a symptom
based approach. In a TB screening exclusively performed in refugees from HBC, only the
patient from Afghanistan, but not the one from Syria would have been detected. In Finnish
screening guidelines, the increased risk for TB in migrants from conflict areas has been taken
into account and all migrants from Syria and Iraq are screened with chest X-ray while other-
wise screening is restricted to countries with a TB incidence of more than 40/100 000 [10].
All patients in our study diagnosed with LTBI received a combination therapy with INH
and RMP for 3 months. The medication was tolerated fairly well, no major side effects were
observed. Hepatotoxicity is the most serious adverse effect related to INH with rare reports on
acute liver failure even during chemopreventive therapy [15]. In previous studies on children
treated with INH for LTBI, asymptomatic elevated liver enzymes were found in 5–10%, with a
higher incidence in adolescents compared to adults [5, 16–20]. Besides INH-dose, disease
severity, slow-acetylator status and co-medication with RMP have been identified as risk fac-
tors for hepatotoxicity [16]. Based on our experience in a German pediatric cohort, chemo-
preventive therapy with INH and RMP is very well tolerated [21].
The impact of chronic hepatitis B infection on antituberculotic drug-induced liver injury is
discussed controversially and has been inconsistently identified as a risk factor for hepatotoxic-
ity [22, 23]. Gray et al. identified abnormal baseline liver function tests to be associated with
INH-associated hepatotoxicity in chemopreventive therapy, but no information on the under-
lying cause of elevated liver enzymes is provided [24]. Increase of liver transaminases above 3
times above the normal upper range was noted in two patients, one being a patient with active
hepatitis B.
The adolescents of our study were accommodated in Berlin only temporarily, facing reloca-
tion at any time. These circumstances are not only reflected in the relatively high number of
persons (n = 9/38) lost to follow-up at the end of chemopreventive treatment but also in the
number of adolescents in whom non-adherence during chemopreventive therapy (n = 10) was
suspected. However, following counselling, non-adherence at the end of chemoprevention was
only suspected in one patient.
Treating LTBI is a cornerstone for elimination of TB in low incidence countries and grow-
ing evidence on tolerability and efficacy of chemopreventive treatment exists [25]. Numerous
studies have shown that a majority of incident TB cases among migrants arise through the
reactivation of LTBI probably acquired outside the host country. Epidemiological evidence
also shows that progression from LTBI to tuberculosis disease usually occurs within the first
two years after arrival [26, 27]. In a recent publication, results of 17 years LTBI screening in
England among non-UK born individuals were evaluated, demonstrating a strong association
between no chemoprophylaxis and developing TB disease [28]. Therefore, screening programs
only aiming to identify adults with active TB neglect addressing the reservoir of tuberculosis
and the risk of transmission of TB within refugee centers and to the resident population [29].
Concerns have arisen about the feasibility of LTBI screening in all pediatric refugees. While
screening for TB infection was feasible in our setting, some patients were lost to follow up dur-
ing chemopreventive treatment. In Germany, it is standard of care to perform a chest X-ray
after completion of chemopreventive treatment. The risk of TB disease following treatment
with INH and RMP has been reported to be approximately 4% and equal to treatment with
INH monotherapy [30]. If a clinical follow-up or repetition of chest X-rays is the most
TB screening and treatment in minor refugees in Germany
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appropriate way to monitor patient for the development of active TB is beyond the scope of
the current study. Recently, data is emerging showing equal efficacy and safety of 3-4months
RMP alone versus 6–9 months of INH with better adherence in the shorter RMP regimen [31].
With this data in mind, adding INH for chemoprevention might add to the risk for hepatoxi-
city without improving efficacy and has come under scrutiny. Nevertheless, there is no clear
evidence demonstrating increased hepatotoxicity rates in children receiving combination ther-
apy. At the time of the study, combination of INH and RMP has been standard therapy in Ger-
many and endorsed by WHO LTBI treatment guidelines [32]
Any screening program faces screening in a high number of migrants to detect those who
actually are infected with tuberculosis or have the disease [33]. For LTBI screening, the body of
evidence for implementation, impact and cost-effectiveness as predicted in mathematical
models is still limited and setting-specific [34, 35]. However, evidence exists for cost-effective-
ness of school-based tuberculosis screening programs for children migrating to low-incidence
countries [36]. For the greatest individual and public health benefits, more emphasis must be
placed on strategies not only to ensure screening but also to facilitate treatment completion.
In summary, we report on a cohort of minor refugees originating from high but also from
low TB burden countries with a high incidence of TB and LTBI. Screening for TB infection
instead of TB disease was feasible and chemopreventive treatment with 3 months of INH and
RMP tolerated well regardless of underlying hepatitis B status. Minor refugees migrating to
Germany should be screened for TB infection, instead of TB disease only regardless of the
background TB incidence. For the greatest individual and public health benefits, more empha-
sis must be placed on strategies not only to ensure screening but also to facilitate treatment
completion.
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